Dyskinesia – Pipeline Review, H2 2019 : ResearchByMarkets.com

Research By Markets adds Market Research Report - Dyskinesia – Pipeline Review, H2 2019 : ResearchByMarkets.com

For detailed information: https://www.researchbymarkets.com/report/dyskinesia-pipeline-review-h2-2019-452513.html

Dyskinesia – Pipeline Review, H2 2019


Dyskinesia – Pipeline Review, H2 2019, provides an overview of the Dyskinesia (Central Nervous System) pipeline landscape.

Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing and tongue thrusting. The disease can be controlled by healthy life style and medication.

Report Highlights

Dyskinesia – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Dyskinesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyskinesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 16, 9, 22 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Dyskinesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


– The pipeline guide provides a snapshot of the global therapeutic landscape of Dyskinesia (Central Nervous System).
– The pipeline guide reviews pipeline therapeutics for Dyskinesia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Dyskinesia (Central Nervous System) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Dyskinesia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Dyskinesia (Central Nervous System)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Dyskinesia (Central Nervous System).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Dyskinesia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned:
Addex Therapeutics Ltd
Amarantus Bioscience Holdings Inc
Astraea Therapeutics LLC
Cadent Therapeutics Inc
Cannabis Science Inc
Cavion LLC
Cerevance Inc
Clevexel Pharma SAS
Contera Pharma ApS
EpiVax Inc
GW Pharmaceuticals Plc
H. Lundbeck AS
Hua Medicine Shanghai Ltd
Ipsen SA
IRLAB Therapeutics AB
Junaxo Inc
Med-Life Discoveries LP
Medytox Inc
Melior Pharmaceuticals II LLC
Merz Pharma GmbH & Co KgaA
MitoDys Therapeutics Ltd
Motac Neuroscience Ltd
NeurAxon Pharma Inc
Neurim Pharmaceuticals Ltd
Neurocea Pharmaceuticals
Neurocrine Biosciences Inc
Neurolixis Inc
Newron Pharmaceuticals SpA
Nissan Chemical Corp
OB Pharmaceuticals
Peptron Inc
PolyCore Therapeutics LLC
Praxis Precision Medicines Australia Pty Ltd
Prilenia Therapeutics Development Ltd
Revance Therapeutics Inc
Sage Therapeutics Inc
SalubRx Therapeutics Inc
Sinopia Biosciences Inc
SOM Biotech SL
Sosei Heptares
Trevi Therapeutics Inc
Ultragenyx Pharmaceutical Inc
VistaGen Therapeutics Inc

For queries regarding this report: https://www.researchbymarkets.com/sample-request/452513

Contact Us:
Sales Desk
USA: +1-800-416-3124

Follow us on Social Media:
Facebook: https://www.facebook.com/researchbymarkets/
LinkedIn: https://www.linkedin.com/company/researchmarkets
Twitter: https://twitter.com/ResearchByMrkts

Ritesh Tiwari is the Founder of Research By Markets, a leading Market Research Reports Reseller trusted by Fortune listed companies for their requirements of Syndicated and Custom Market Research Reports. Ritesh has an overall experience of 18+ years in Recruitments, Sales and Operations. He has been associated with the Market Research industry for the past 7 years. He is an avid foodie as well as a huge football fan being a supporter of Manchester United (EPL) and FC Barcelona (La Liga). Get in touch with him via ritesh@researchbymarkets.com. *Market Research News is a part of Research By Markets.